Get the Stockscreener App
1.42
4.05%
-0.06
Calidi Biotherapeutics Inc stock is traded at $1.42, with a volume of 1.19M.
It is down -4.05% in the last 24 hours and down -3.40% over the past month.
Calidi Biotherapeutics Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is headquartered in San Diego, California.
See More
Previous Close:
$1.48
Open:
$1.31
24h Volume:
1.19M
Relative Volume:
0.55
Market Cap:
$38.35M
Revenue:
-
Net Income/Loss:
$-23.36M
P/E Ratio:
-1.9273
EPS:
-0.7368
Net Cash Flow:
-
1W Performance:
+87.29%
1M Performance:
-3.40%
6M Performance:
-12.35%
1Y Performance:
-77.50%
1-Day Range:
$1.25
$1.43
1-Week Range:
$0.7221
$1.50
52-Week Range:
$0.58
$16.80
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Name
Calidi Biotherapeutics Inc
Sector
Industry
Phone
(858) 794-9600
Address
4475 Executive Drive, Suite 200, San Diego
Compare CLDI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
1.425 | 38.35M | 0 | -23.36M | 0 | -0.7368 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.13 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
719.93 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.85 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.66 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.25 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-23 | Initiated | H.C. Wainwright | Buy |
| Oct-09-23 | Initiated | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Stock (CLDI) Latest News
Calidi Biotherapeutics expands stock offering capacity - Investing.com India
Calidi Biotherapeutics expands stock offering capacity By Investing.com - Investing.com South Africa
Market Recap: Calidi Biotherapeutics Inc (CLDI)’s Positive Momentum, Closing at 1.32 - The Dwinnex
For Calidi Biotherapeutics Inc [CLDI], Analyst sees a rise to $11. What next? - The DBT News
Calidi Biotherapeutics Inc Inc. (CLDI) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Get in on Calidi Biotherapeutics Inc’s (CLDI) buy-in window today! - SETE News
Taking a Closer Look At Calidi Biotherapeutics Inc (CLDI) Following Its Recent Trade - Knox Daily
CLDI’s price-to-sales ratio: A comparative analysis with its peers - US Post News
CLDI Stock Plummets to 52-Week Low at $0.6 Amid Market Turbulence - Investing.com Australia
Calidi Biotherapeutics Bolsters Cash Balance and Terminates Standby Equity Purchase AgreementSAN DIEGO, January 28, 2025 – Calidi Biotherapeutics Inc. (NYSE American: CLDI) recently disclosed the ending cash balance amounting to approximately $ - Defense World
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5 - The Manila Times
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5 - GlobeNewswire
Inside Calidi's Game-Changing Cancer Treatment Pipeline: Top Execs Reveal Next-Gen Therapies - StockTitan
CLDICalidi Biotherapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Calidi Biotherapeutics Ends SEPA After Successful Fundraising - TipRanks
Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement - GlobeNewswire
Cancer Biotech Raises $18.8M War Chest to Fast-Track Revolutionary Brain Cancer Treatment - StockTitan
Why Calidi Biotherapeutics Inc (AMEX: CLDI) Is A Great Stock Pick For Momentum Investors - Stocks Register
Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
CLDI stock touches 52-week low at $0.73 amid market challenges - MSN
The Business Case For Buying Calidi Biotherapeutics Inc (AMEX: CLDI) Stock Now - Stocks Register
Calidi Biotherapeutics Announces Presentation of New Data - GlobeNewswire
Calidi Biotherapeutics to Present Breakthrough Cancer Treatment Platform at AACR 2025 Meeting - StockTitan
Calidi Biotherapeutics announces reverse stock split adjustment - Investing.com
Calidi Biotherapeutics (NYSE American: CLDI) Prices $4.25 Million Public Offering - The Globe and Mail
Calidi Biotherapeutics Announces $4.25 Million Public Stock Offering - Defense World
Calidi Biotherapeutics Refiles Consolidated Financial Statements After Reverse Stock Split - Defense World
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock - The Bakersfield Californian
Calidi Biotherapeutics Raises $4.25M Through Public Offering of Common Stock at $0.85 Per Share - StockTitan
Why Calidi Biotherapeutics (CLDI) Stock Is Down 30% - Benzinga
Calidi Biotherapeutics slumps 29%, prices $4.25M stock offering - MSN
Calidi Biotherapeutics Announces Public Stock Offering Deal - TipRanks
Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock - The Bakersfield Californian
Calidi Biotherapeutics Raises $4.25M Through Public Offering to Advance Cancer Immunotherapy Platform - StockTitan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Calidi Biotherapeutics (NYSE:CLDI) Stock Price Down 8.2% – Should You Sell? - Defense World
Calidi Biotherapeutics Announces Proposed Public Offering - The Manila Times
Calidi Biotherapeutics Announces Common Stock Public Offering to Advance Immunotherapy Pipeline - StockTitan
Reviewing Calidi Biotherapeutics (NYSE:CLDI) & iTeos Therapeutics (NASDAQ:ITOS) - Defense World
Comparing Calidi Biotherapeutics (NYSE:CLDI) & Immatics (NASDAQ:IMTX) - Defense World
Calidi Biotherapeutics CEO Allan Camaisa sells $16,200 in stock - Investing.com India
Calidi Biotherapeutics prices $7.5M secondary offering - MSN
Calidi Biotherapeutics Inc (CLDI-A) QuotePress Release - The Globe and Mail
Calidi Biotherapeutics (NYSE American: CLDI) Data Demonstrates Potential of Innovative Solutions to Revolutionize Cancer Care - Barchart
UMACUnusual Machines, Inc. Latest Stock News & Market Updates - StockTitan
Calidi Biotherapeutics Inc Stock (CLDI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.46%
Cap:
|
Volume (24h):